公开(公告)号：EP2832355A1

公开(公告)日：2015-02-04

申请号：EP13767892.6

申请日：2013-03-26

申请人： Kracie Pharma, Ltd. ,  National Cancer Center ,  National University Corporation University of Toyama

发明人： ESUMI Hiroyasu ,  IKEDA Masafumi ,  MIYOSHI Chika ,  KADOTA Shigetoshi ,  OKUBO Toshiki ,  YOMODA Satoshi ,  FUSE Takafumi ,  KAWASHIMA Takanori ,  CHIBA Shigeki

IPC分类号： A61K31/341 ,  A61K31/7034 ,  A61K36/00 ,  A61K36/28 ,  A61P35/00

CPC分类号： A61K31/7048 ,  A61K31/341 ,  A61K31/365 ,  A61K31/7034 ,  A61K36/28 ,  A61K2300/00

摘要： The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin = 0.7 to 1.3.

摘要翻译： 本发明旨在提供对癌症有效的新型抗癌剂。 将使用牛蒡子提取物制备的药剂以每天100mg以上的剂量给予胰腺癌患者后，观察到肿瘤降低效果，确认肿瘤标志物的降低。 本发明提供了含有牛蒡子苷元的抗癌剂，其中牛蒡子苷元的剂量为每天100mg或更多。 此外，本发明提供了含有牛蒡子苷元/牛蒡子苷= 0.7至1.3的重量比的含有牛蒡子苷元和牛蒡子苷的抗癌剂。